Question 1

What is UBLITUXIMAB used for?

Accepted Answer

UBLITUXIMAB (brand name BRIUMVI) is a Other indicated for 1 INDICATIONS AND USAGE BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease.

Question 2

How does UBLITUXIMAB work?

Accepted Answer

UBLITUXIMAB works through the following mechanism: 12.1 Mechanism of Action The precise mechanism by which ublituximab-xiiy exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ublituximab-xiiy results in cell lysis through mechanisms including antibody-dependent cellular cytolysis and complement-dependent cytolysis..

Question 3

What are the most common side effects of UBLITUXIMAB?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for UBLITUXIMAB. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is UBLITUXIMAB the same as BRIUMVI?

Accepted Answer

BRIUMVI is a brand name for UBLITUXIMAB. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

UBLITUXIMAB

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations